Rawal Sudhir K, Khanna Ashish, Singh Amitabh, Pratihar Sarbartha K, Malla Ishan, Ali Mujahid, Vasudeo Vivek, Jaganthan Kaushik, Kumar Bhuvan, Saurabh Nikhil
Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India.
Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India.
Asian J Urol. 2025 Apr;12(2):143-151. doi: 10.1016/j.ajur.2024.04.009. Epub 2024 Nov 13.
To report our preliminary clinical experience and outcomes of uro-oncology procedures conducted utilizing the SSI Mantra™ surgical robotic system.
Data of consecutive patients who underwent various robot-assisted uro-oncology procedures using the SSI Mantra™ surgical robotic system at our institution between July 2022 and September 2023 were recorded. The specific surgical configurations employed with the SSI Mantra™ for these procedures were duly noted. We assessed the feasibility of these procedures with this novel surgical robotic system and report the outcomes.
A total of 156 patients were operated with the SSI Mantra™ surgical robotic system. The spectrum of procedures performed comprised robot-assisted laparoscopic radical prostatectomy with bilateral extended pelvic lymph node dissection (=77), robot-assisted radical cystectomy with bilateral extended pelvic lymph node dissection with extracorporeal urinary diversion (=39), robot-assisted radical nephrectomy (=32), robot-assisted partial nephrectomy (=6), robot-assisted radical nephroureterectomy with bladder cuff excision (=1), and bilateral robot-assisted video endoscopic inguinal lymph node dissection (=1). One robot-assisted laparoscopic radical prostatectomy had to be converted to open in view of system malfunction. However, no system-related intraoperative complications or injuries were encountered.
The SSI Mantra™ surgical robotic system demonstrates significant promise as an innovative robotic platform. In this single-center experience, we have demonstrated the feasibility of a diverse array of surgical procedures using this platform. Further research, involving a larger cohort of patients, is imperative to refine the operative techniques and comprehensively understand the perioperative outcomes of the SSI Mantra™ surgical robotic system, particularly in comparison to other robotic surgical platforms.
报告我们使用SSI Mantra™手术机器人系统进行泌尿肿瘤手术的初步临床经验和结果。
记录2022年7月至2023年9月期间在我们机构使用SSI Mantra™手术机器人系统接受各种机器人辅助泌尿肿瘤手术的连续患者的数据。详细记录了在这些手术中与SSI Mantra™一起使用的具体手术配置。我们评估了使用这种新型手术机器人系统进行这些手术的可行性并报告结果。
共有156例患者使用SSI Mantra™手术机器人系统进行了手术。所进行的手术范围包括机器人辅助腹腔镜根治性前列腺切除术并双侧扩大盆腔淋巴结清扫术（=77例）、机器人辅助根治性膀胱切除术并双侧扩大盆腔淋巴结清扫术及体外尿流改道术（=39例）、机器人辅助根治性肾切除术（=32例）、机器人辅助部分肾切除术（=6例）、机器人辅助根治性肾输尿管切除术并膀胱袖口切除术（=1例）以及双侧机器人辅助视频内镜腹股沟淋巴结清扫术（=1例）。由于系统故障，1例机器人辅助腹腔镜根治性前列腺切除术不得不转为开放手术。然而，未遇到与系统相关的术中并发症或损伤。
SSI Mantra™手术机器人系统作为一个创新的机器人平台显示出巨大的前景。在这项单中心经验中，我们证明了使用该平台进行各种手术的可行性。进一步的研究，涉及更大规模的患者队列，对于完善手术技术和全面了解SSI Mantra™手术机器人系统的围手术期结果至关重要，特别是与其他机器人手术平台相比。
